Aldose reductase structures: implications for mechanism and inhibition

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cellular and Molecular Life Sciences (CMLS)

• Publication date

  2004-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00018-003-3403-2PMID 15095000PMCID PMC11138662
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.

  2009cited by this paper
• Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.

  2009cited by this paper
• Antibiotics for the prophylaxis of bacterial endocarditis in dentistry.

  2008cited by this paper
• Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.

  2007cited by this paper
• Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.

  2007cited by this paper
• The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS).

  2007cited by this paper
• Prevention of Infective Endocarditis

  2007cited by this paper
• Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

  2006cited by this paper
• Isolates with Low-Level Vancomycin Resistance Associated with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

  2006cited by this paper
• The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials.

  2006cited by this paper
• Staphylococcus aureus endocarditis: a consequence of medical progress.

  2005cited by this paper
• Infective endocarditis

  2004cited by this paper
• β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

  2004cited by this paper
• [S2 Guideline for diagnosis and therapy of infectious endocarditis].

  2004cited by this paper
• Binding of 1-benzopyran-4-one derivatives to aldose reductase: a free energy perturbation study.

  2002cited by this paper
• On the prodrug potential of novel aldose reductase inhibitors with diphenylmethyleneaminooxycarboxylic acid structure.

  2002cited by this paper
• The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat.

  2002cited by this paper
• Discovery of new inhibitors of aldose reductase from molecular docking and database screening.

  2002cited by this paper
• Structure of human aldose reductase holoenzyme in complex with Statil: An approach to structure‐based inhibitor design of the enzyme

  2002cited by this paper
• Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications

  2002cited by this paper
• Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.

  2002cited by this paper
• Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin‐induced diabetic rat tissues

  2001cited by this paper
• Discovery of novel aldose reductase inhibitors using a protein structure-based approach: 3D-database search followed by design and synthesis.

  2001cited by this paper
• Structural and kinetic modifications of aldose reductase by S-nitrosothiols.

  2001cited by this paper
• 7-Hydroxy-2-substituted-4-H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: a SAR study.

  2001cited by this paper
• Protein structure-based de novo design and synthesis of aldose reductase inhibitors.

  2001cited by this paper
• The role of aldose reductase inhibitors in diabetic complications: recent trends.

  2001cited by this paper
• Aldose Reductase Inhibitors

  2001cited by this paper
• [1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.

  2001cited by this paper
• Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.

  2001cited by this paper
• Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

  2000cited by this paper
• Nitric oxide and vascular responses in Type I diabetes

  2000cited by this paper
• Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.

  2000cited by this paper
• The sorbinil trap: a predicted dead-end complex confirms the mechanism of aldose reductase inhibition.

  2000cited by this paper
• Aldose and aldehyde reductases: Correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site

  2000cited by this paper
• A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography.

  2000cited by this paper
• The structure of human aldose reductase bound to the inhibitor IDD384.

  2000cited by this paper
• Aldose reductase and the role of the polyol pathway in diabetic nephropathy.

  2000cited by this paper
• Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads.

  2000cited by this paper
• The Protein Data Bank

  2000cited by this paper
• The missing link: a single unifying mechanism for diabetic complications.

  2000cited by this paper
• LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design

  2000cited by this paper
• Computer Simulation Studies of the Catalytic Mechanism of Human Aldose Reductase

  2000cited by this paper
• Pharmacological approaches to the treatment of diabetic complications

  2000cited by this paper
• Model of the catalytic mechanism of human aldose reductase based on quantum chemical calculations

  2000cited by this paper
• Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.

  1999cited by this paper
• Contributions of polyol pathway to oxidative stress in diabetic cataract

  1999cited by this paper
• Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans.

  1999cited by this paper
• Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies

  1999cited by this paper
• Modelling the catalytic reaction in human aldose reductase

  1999cited by this paper
• 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors.

  1999cited by this paper
• Phenylsulfonylnitromethanes as potent irreversible inhibitors of aldose reductase

  1999cited by this paper
• Aldose reductase inhibitors: therapeutic implications for diabetic complications.

  1999cited by this paper
• Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches

  1999cited by this paper
• Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.

  1998cited by this paper
• SCORE: A New Empirical Method for Estimating the Binding Affinity of a Protein-Ligand Complex

  1998cited by this paper
• Free energy perturbation studies on binding of the inhibitor 5,6-dihydrobenzo[h]cinnolin-3(2H)one-2-acetic acid and its methoxylated analogs to aldose reductase

  1998cited by this paper
• Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.

  1998cited by this paper
• Protein kinase C activation and the development of diabetic complications.

  1998cited by this paper
• Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis.

  1998cited by this paper
• Catalytic mechanism of aldose reductase studied by the combined potentials of quantum mechanics and molecular mechanics.

  1998cited by this paper
• Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

  1998cited by this paper
• Bacteraemia following local anaesthetic injections in children

  1998cited by this paper
• Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.

  1998cited by this paper
• Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase.

  1998cited by this paper
• Mutagenesis of 3 alpha-hydroxysteroid dehydrogenase reveals a "push-pull" mechanism for proton transfer in aldo-keto reductases.

  1998cited by this paper
• Studies on the inhibitor‐binding site of porcine aldehyde reductase: Crystal structure of the holoenzyme‐inhibitor ternary complex

  1997cited by this paper
• Physiological substrates of human aldose and aldehyde reductases.

  1997cited by this paper
• Worldwide pharmacovigilance systems and tolrestat withdrawal.

  1997cited by this paper
• The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.

  1997cited by this paper
• Aldose Reductase Inhibitors: The End of an Era or the Need for Different Trial Designs?

  1997cited by this paper
• A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.

  1997cited by this paper
• Structure-based design of an inhibitor modeled at the substrate active site of aldose reductase

  1997cited by this paper
• Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats

  1996cited by this paper
• Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.

  1996cited by this paper
• The cellular and molecular mechanisms of diabetic complications.

  1996cited by this paper
• The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity.

  1996cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• Structure of porcine aldehyde reductase holoenzyme

  1995cited by this paper
• Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme.

  1994cited by this paper
• Rational automatic search method for stable docking models of protein and ligand.

  1994cited by this paper
• An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate.

  1994cited by this paper
• New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service.

  1994cited by this paper
• General atomic and molecular electronic structure system

  1993cited by this paper
• A perspective of aldose reductase inhibitors

  1993cited by this paper
• Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.

  1993cited by this paper
• Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation.

  1993cited by this paper
• FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA

  1993cited by this paper
• Aldose reductase inhibitors: recent developments.

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• The computer program LUDI: A new method for the de novo design of enzyme inhibitors

  1992cited by this paper
• An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications.

  1992cited by this paper
• Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80, -298, and -303.

  1992cited by this paper
• Novel NADPH-binding domain revealed by the crystal structure of aldose reductase

  1992cited by this paper
• Structure-Based Strategies for Drug Design and Discovery

  1992cited by this paper
• Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease.

  1991cited by this paper
• Expression of human aldose and aldehyde reductases. Site-directed mutagenesis of a critical lysine 262.

  1991cited by this paper
• Computer Modeling of Chemical Reactions in Enzymes and Solutions

  1991cited by this paper
• In-vitro assessment of a hypersensitivity syndrome associated with sorbinil.

  1991cited by this paper
• Inhibition of aldehyde reductase by aldose reductase inhibitors.

  1990cited by this paper

• Unveiling the medicinal diversity of benzoic acid containing molecules: Insights on druggable targets for type 2 diabetes mellitus.

  2025cites this paper
• A New Method of Synthesis of Epalrestat

  2025cites this paper
• Unveiling the Role of Schwann Cell Plasticity in the Pathogenesis of Diabetic Peripheral Neuropathy

  2024cites this paper
• Selectivity Challenges for Aldose Reductase Inhibitors: A Review on Comparative SAR and Interaction Studies

  2024cites this paper
• Mechanism of Inhibitory Effects of Phellodendrine on Diabetes Mellitus Using Molecular Docking Method

  2024cites this paper
• Studi Molecular Docking dan Evaluasi Farmakokinetik Senyawa Analog Pirazol Turunan Benzen-Sulfonilurea sebagai Inhibitor Enzim Aldose Reduktase and α-Glukosidase Menggunakan Pendekatan In Silico

  2024cites this paper
• Mechanism of AGT-Mediated Repair of dG-dC Cross-Links in the Drug Resistance to Chloroethylnitrosoureas: Molecular Docking, MD Simulation, and ONIOM (QM/MM) Investigation

  2024cites this paper
• SUPERCRITICAL FLUID EXTRACTION OF GINGER HERBAL DUST BIOACTIVES WITH ESTIMATION OF PHARMACOLOGICAL POTENTIAL USING IN SILICO AND IN VITRO ANALYSIS

  2024cites this paper
• Quantification of total phenols in Coleus forskohlii and Inhibition of Aldose Reductase by Rosmarinic acid.

  2024cites this paper
• Predictive Value of Multi-Phase CT Radiomics in Delineating Early and Advanced T Staging of Colon Cancer

  2024influential citation
• Identification of Potential Aldose Reductase Inhibitors Using Convolutional Neural Network-Based in Silico Screening

  2023cites this paper
• Biochemical Analysis and Human Aldose Reductase Inhibition Activity of Selected Medicinal Plants of Nepal

  2023cites this paper
• Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections

  2023cites this paper
• 6D-QSAR for predicting biological activity of human aldose reductase inhibitors using quasar receptor surface modeling

  2023cites this paper
• Risk factors for eye lens opacity in nuclear medicine workers – An overview

  2023cites this paper
• UNRAVELING ANTI-DIABETIC AND PHARMACOLOGICAL PROPERTIES OF GREEN GEDI, LEILEM, AND SESEWANUA USING A PHARMACOINFORMATICS APPROACH

  2022cites this paper
• Strategies in synthetic design and structure–activity relationship studies of novel heterocyclic scaffolds as aldose reductase‐2 inhibitors

  2022cites this paper
• Natural Antioxidant Activities of Plants in Preventing Cataractogenesis

  2022cites this paper
• Structure-Based Virtual Screening for Differential Inhibition of Aldose Reductase, Implicated in Secondary Complications in Diabetes

  2021cites this paper
• Dietary aldose reductase inhibitors and prevention of diabetic complications

  2021cites this paper
• Synthesis, molecular modeling, selective aldose reductase inhibition and hypoglycemic activity of novel meglitinides.

  2021cites this paper
• Synthesis and Anticancer Activity of 2-Cyano-N-(furan-2-ylmethyl)-2-(4-oxo-3-arylthiazolidin-2-ylidene)acetamide Derivatives

  2021cites this paper
• ALTERATIONS OF ALDOSE REDUCTASE ACTIVITY BY INDOLE-3-CARBOXALDEHYDE DERIVATIVES

  2021cites this paper
• Multi-Targeted Molecular Docking, Pharmacokinetics, and Drug-Likeness Evaluation of Okra-Derived Ligand Abscisic Acid Targeting Signaling Proteins Involved in the Development of Diabetes

  2021cites this paper
• Inhibition Profiles and Molecular Docking Studies of Anti-proliferative Agents Against Aldose Reductase Enzyme

  2021cites this paper
• Aldose Reductase: a cause and a potential target for the treatment of diabetic complications

  2021cites this paper
• Molecular Docking of Polyphenol Compounds from Anacardium occidentale with Alpha-Glucosidase and Dipeptidyl-Peptidase-4 Enzymes

  2021cites this paper
• Poncirin, an orally active flavonoid exerts antidiabetic complications and improves glucose uptake activating PI3K/Akt signaling pathway in insulin resistant C2C12 cells with anti-glycation capacities.

  2020cites this paper
• Phytosterols of marine algae: Insights into the potential health benefits and molecular pharmacology.

  2020cites this paper
• Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications.

  2020cites this paper
• Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.

  2020cites this paper
• Rhodanine-3-Acetamide Derivatives as Aldose and Aldehyde Reductase Inhibitors to Treat Diabetic Complications; Synthesis, Biological Evaluation and Molecular Docking Studies

  2020cites this paper
• (4-oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors.

  2020cites this paper
• Relationship between aldose reductase enzyme and the signaling pathway of protein kinase C in the in vitro diabetic retinopathy model.

  2019cites this paper
• Aldose reductase inhibitors: 2013-present

  2019cites this paper
• The Fate of Aldose Reductase Inhibition and Sorbitol Dehydrogenase Activation

  2019cites this paper
• Contribution of Aldose Reductase-Mediated Oxidative Stress Signaling in Inflammatory Lung Diseases

  2019cites this paper
• Understanding Aldose Reductase-Inhibitors interactions with free energy simulation.

  2019cites this paper
• Didymin, a dietary citrus flavonoid exhibits anti-diabetic complications and promotes glucose uptake through the activation of PI3K/Akt signaling pathway in insulin-resistant HepG2 cells.

  2019cites this paper
• Synthesis and Aldose Reductase Inhibitory Effect of Some New Hydrazinecarbothioamides and 4-Thiazolidinones Bearing an Imidazo[2,1-b]Thiazole Moiety

  2018cites this paper
• The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10

  2018cites this paper
• Pharmacological Modulation of Long Cardiac QT Interval in Ex Vivo and in Vitro Experimental Models

  2018cites this paper
• Edible vegetables as a source of aldose reductase differential inhibitors.

  2017cites this paper
• New Insights into the Catalytic Mechanism of Aldose Reductase: A QM/MM Study

  2017cites this paper
• Synthesis and Functional Evaluation of Novel Aldose Reductase Inhibitors Bearing a Spirobenzopyran Scaffold

  2017cites this paper
• N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase.

  2017cites this paper
• 5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistry

  2017cites this paper
• Construction of explicit models to correlate the structure and the inhibitory activity of aldose reductase: Flavonoids and sulfonyl‐pyridazinones as inhibitors

  2017cites this paper
• Novel quinazolinone-based 2,4-thiazolidinedione-3-acetic acid derivatives as potent aldose reductase inhibitors.

  2017cites this paper
• SYNTHESIS AND EVALUATION OF SOME NEW 2-( 5-( 4-BENZAMIDOBENZYLIDENE )-2 , 4-DIOXOTHIAZOLIDIN-3-YL ) ACETIC ACID ANALOGS AS ALDOSE REDUCTASE INHIBITORS

  2017cites this paper
• Nutraceuticals in prevention of cataract – An evidence based approach

  2016cites this paper
• Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins

  2016cites this paper
• Synthetic Development of New 3-(4-Arylmethylamino)butyl-5-arylidene-rhodanines under Microwave Irradiation and Their Effects on Tumor Cell Lines and against Protein Kinases

  2015cites this paper
• Synthesis, characterization, hypoglycemic and aldose reductase inhibition activity of arylsulfonylspiro[fluorene-9,5'-imidazolidine]-2',4'-diones.

  2015cites this paper
• Searching for Growth Conditions for Optimized Expression of Recombinant Proteins in Escherichia coli by Using Two-Dimensional NMR Spectroscopy

  2015cites this paper
• Inhibition of advanced glycation endproducts formation by Korean thistle, Cirsium maackii.

  2015cites this paper
• Design, Synthesis and Evaluation of Rhodanine Derivatives as Aldose Reductase Inhibitors

  2015cites this paper
• Synthesis of optically pure (S)-2-amino-5-arylpent-4-ynoic acids by Sonogashira reactions and their potential use as highly selective potent inhibitors of aldose reductase

  2015cites this paper
• Molecular docking studies of (4Z, 12Z)-cyclopentadeca-4, 12-dienone from Grewia hirsuta with some targets related to type 2 diabetes

  2015cites this paper
• Binding Mode Investigation of Polyphenols from Scrophularia Targeting Human Aldose Reductase Using Molecular Docking and Molecular Dynamics Simulations

  2015cites this paper
• Kinetic and molecular docking studies of loganin and 7-O-galloyl-d-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase

  2015cites this paper
• Inhibitory effect of eleven herbal extracts on advanced glycation end-products formation and aldose reductase activity

  2014cites this paper
• Evaluation of in vitro aldose reductase inhibitory potential of alkaloidal fractions of Piper nigrum, Murraya koenigii, Argemone mexicana, and Nelumbo nucifera

  2014cites this paper
• Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis

  2014cites this paper
• New 5-ylidene rhodanine derivatives based on the dispacamide A model

  2014cites this paper
• Evaluation of ranirestat for the treatment of diabetic neuropathy

  2014cites this paper
• A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications.

  2014cites this paper
• Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.

  2014cites this paper
• Induced fit docking, pharmacophore modeling, and molecular dynamic simulations on thiazolidinedione derivatives to explore key interactions with Tyr48 in polyol pathway

  2014cites this paper
• Molecular docking analysis of embelin and its metal complexes as human aldose reductase (HAR) inhibitor

  2014cites this paper
• In vitro inhibitory effects of cranberry bean (Phaseolus vulgaris L.) extracts on aldose reductase, α‐glucosidase and α‐amylase

  2014cites this paper
• Kinetic and molecular docking studies of loganin and 7-O-galloyl-d-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase

  2014influential citation
• Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.

  2013cites this paper
• Diabetic Retinopathy: Its Progression and the Effective Treatment to Prevent Blindness

  2013cites this paper
• A novel combined pharmacophore mapping and quantitative structure selectivity relationship analysis for the development of potent and selective human aldose reductase inhibitors.

  2013cites this paper
• A New Approach to Control the Enigmatic Activity of Aldose Reductase

  2013cites this paper
• Challenges in docking 2′-hydroxy and 2′,4′-dihydroxychalcones into the binding site of ALR2

  2013influential citation
• Synthesis of derivatives of the keto-pyrrolyl-difluorophenol scaffold: some structural aspects for aldose reductase inhibitory activity and selectivity.

  2013cites this paper
• Aldose Reductase, Oxidative Stress, and Diabetic Mellitus

  2012cites this paper
• Induced fit binding of aldose reductase inhibitors to AKR1B10

  2012cites this paper
• Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.

  2012cites this paper
• Evaluation of in vitro aldose reductase inhibitory potential of different fraction of Hybanthus enneaspermus Linn F. Muell.

  2012cites this paper
• Affinity-based profiling of dehydrogenase subproteomes.

  2012cites this paper
• Aldose reductase regulates TNF-α-induced inducible nitric oxide synthase expression in human mesangial cells

  2012cites this paper
• Promising antidiabetic potential of fucoxanthin isolated from the edible brown algae Eisenia bicyclis and Undaria pinnatifida

  2012cites this paper
• Chelation: A Fundamental Mechanism of Action of AGE Inhibitors, AGE Breakers, and Other Inhibitors of Diabetes Complications

  2012cites this paper
• Ligand-induced fit affects binding modes and provokes changes in crystal packing of aldose reductase.

  2011cites this paper
• Tracing the detail: how mutations affect binding modes and thermodynamic signatures of closely related aldose reductase inhibitors.

  2011cites this paper
• Radiation damage reveals promising interaction position.

  2011cites this paper
• Protein Tyrosine Phosphatase 1B and α-Glucosidase Inhibitory Phlorotannins from Edible Brown Algae, Ecklonia stolonifera and Eisenia bicyclis

  2011cites this paper
• Inhibitory Properties of Functional Food Plants on CYP Enzymes and Cree Traditional Medicines on Aldose Reductase

  2011cites this paper
• Eye Lens in Aging and Diabetes: Effect of Quercetin

  2011cites this paper
• - 1-Structure-based enzyme inhibition mechanism studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors using kinetics and molecular docking modeling

  2011influential citation
• Extraction and identification of three major aldose reductase inhibitors from Artemisia montana.

  2011cites this paper
• Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract

  2011cites this paper
• Role of aldose reductase in the high glucose induced expression of fibronectin in human mesangial cells

  2010cites this paper
• Aldose reductase is a potent regulator of TGF-β1 induced expression of fibronectin in human mesangial cells

  2010cites this paper
• Prevention of posterior capsular opacification through aldose reductase inhibition.

  2009cites this paper
• Diabetic Peripheral Neuropathy-emerging Pharmacologic Options

  2008cites this paper
• Approximate similarity and QSAR in the study of spirosuccinimide type aldose reductase inhibitors

  2008cites this paper